Q3 2025 Earnings Call Transcript: IceCure Medical's Operational Highlights and Financial Results

IceCure Medical reported Q3 2025 earnings, with CEO Eyal Shamir and CFO Ronen Tsimerman participating in a conference call. The company expects the FDA's marketing authorization process to drive growth, support broader access for patients, and believes that ProSense will be the only cryoablation system cleared in the US for breast cancer in the foreseeable future. Terumo Corporation is expected to submit regulatory applications for ProSense in Japan.